Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MOMICS trial to predict blood pressure response to antihypertensive drugs
2023-505239-10-00Phase 4Authorised
- Sponsor
- Radboud University Medical Center
- Start
- Mar 2024
- Modality
- Small Molecules
- Countries
- 2
01
Overview
Phase 4, open-label trial of olmesartan, amlodipine, hydrochlorothiazide and olmesartan medoxomil + amlodipine in essential hypertension (4 arms), sponsored by Radboud University Medical Center. Primary endpoint: Predictive value of MOMICs profile for 24-hour blood pressure response. Planned start Mar 2024; status: authorised.
02
Drugs
olmesartanamlodipinehydrochlorothiazideolmesartan medoxomil + amlodipine
03
Conditions
essential hypertension
Beyond the preview
Go deeper on 2023-505239-10-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-505239-10-00.